Towards fast and inexpensive molecular diagnostic: The case of TP53

Clinica Chimica Acta

Volumn 343, Issue 1-2, 2004, Pages 45-60

  Jiang, Tieshan ^a,b   Minunni, Maria ^b   Mascini, Marco ^b  

^a HUNAN NORMAL UNIVERSITY   (China)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Biosensor; Detection of mutations; Gene chip; TP53

Indexed keywords

BIOLOGICAL MARKER;

ALLELE; BIOSENSOR; CANCER DIAGNOSIS; CAPILLARY ELECTROPHORESIS; DENATURING GRADIENT GEL ELECTROPHORESIS; DIAGNOSTIC PROCEDURE; DNA SEQUENCE; ELECTROCHEMICAL DETECTION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HETERODUPLEX ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSENSOR; PIEZOELECTRICITY; PRIORITY JOURNAL; REVIEW; SURFACE PLASMON RESONANCE; TUMOR SUPPRESSOR GENE;

DNA MUTATIONAL ANALYSIS; HUMANS; MOLECULAR PROBE TECHNIQUES; NEOPLASMS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 2042474778     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cccn.2004.01.018     Document Type: Review

References (82)

1. Camplejohn R.S., Rutherford J. p53 functional assays: detecting p53 mutations in both the germline and in sporadic tumours. Cell Prolif. 34(1):2001;1-14
2. Wang X.W., Harris C.C. p53 tumour suppressor gene: clues to molecular carcinogenesis and cancer therapy, Cancer Surveys. Genet. Instab. Cancer. 28:1996;169-196
3. Hainaut P., Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv. Cancer Res. 77:2000;81-137
4. Kubbutat M.H., Jones S.N., Vousden K.H. Regulation of p53 stability by Mdm2. Nature. 387:1997;299-303
5. Stott F.J., Bates S., James M.C., McConnell B.B., Starborg M., Brookes S., et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17:1998;5001-5014
6. Oda K., Arakawa H., Tanaka T., Matsuda K., Tanikawa C., Mori T., et al. p53AIPI, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell. 102:2000;849-862
7. Shieh S.Y., Ikeda M., Taya Y., Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 91:1997;325-334
8. Sanz-Ortega J., Steinberg S.M., Moro E., Saez M., Lopez J.A., Sierra E., et al. Comparative study of tumor angiogenesis and immunohistochemistry for p53, c-ErbB2, c-myc and EGFr as prognostic factors in gastric cancer. Histol. Histopathol. 15:2000;455-462
9. Wright G.S., Gruidl M.E. Early detection and prevention of lung cancer. Curr. Opin. Oncol. 12:2000;143-148
10. Lane D.P. Cancer: p53, guardian of the genome. Nature. 358:1992;15-16
11. Falette N., Paperin M.P., Treilleux I., Gratadour A.C., Peloux N., Mignotte H., et al. Prognostic value of p53 gene mutations in a large series of node-negative breast cancer patients. Cancer Res. 58:1998;1451-1455
12. Walker D.R., Bond J.P., Tarone R.E., Harris C.C., Makalowski W., Boguski M.S., et al. Evolutionary conservation and somatic mutation hotspots maps of p53: correlation with p53 protein structural and functional features. Oncogene. 19:1999;211-218
13. Pfeifer G.P. p53 mutational spectra and the role of methylated CpG sequences. Mutat. Res. 450:2000;155-166
14. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science. 253(5015):1991;49-53
15. van Oijen M.G., Slootweg P.J. Gain-of-function mutations in the tumor suppressor gene p53. Clin. Cancer Res. 6:2000;2138-2145
16. Soussi T., Béroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat. Rev., Cancer. 1:2001;233-240
17. Soussi T., Béroud C. Significance of TP53 mutations in human cancer: a critical analysis of mutations at CpG dinucleotides. Hum. Mut. 21:2003;192-200
18. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature. 408:2000;307-310
19. Bennett W.P., Hussain S.P., Vahakangas K.H., Khan M.A., Shields P.G., Harris C.C. J. Pathol. 187:1999;8-18
20. Blandino G., Levine A.J., Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene. 18:1999;477-485
21. Iacopetta B. TP53 mutation in colorectal cancer. Hum. Mut. 21:2003;271-276. [review]
22. Brantley M.A., Worley L. Jr., Harbour J.W. Altered expression of rb and p53 in uveal melanomas following plaque radiotherapy. Am. J. Ophthalmol. 133(2):2002 (February);242-248
23. Lowe S.W. Cancer therapy and p53. Curr. Opin. Oncol. 7:1995;547-553
24. Lee J.M., Bernstein A. p53 mutations increase resistance to ionizing radiation. Proc. Natl. Acad. Sci. U. S. A. 90:1993;5742-5746
25. Khan Z.A.J., Jonas S.K., Feldman K.A., Patel H., Wharton R.Q., Tarragona A., et al. p53 mutation and response to hepatic arterial floxuridine in patients with colorectal liver metastases. J. Cancer Res. Clin. Oncol. 127:2001;675-680
26. Goh H.S., Yao J., Smith J.R. p53 point mutation and survival in colorectal cancer patients. Cancer Res. 55:1995;5217-5221
27. Peller S. Clinical implications of p53: effect on prognosis, tumour progression and chemotherapy response. Semin. Cancer Biol. 8:1998;379-387. [review]
28. Aas T., Børresen-Dale A.L., Geisler S., Smith-Sørensen B., Johnsen H., Varhaug J.E., et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med. 2:1996;811-814
29. Børresen-Dale A.L. TP53 and beast cancer. Hum. Mutat. 21:2003;292-300. [review]
30. Rahko E., Blanco G., Soini Y., Bloigu R., Jukkola A. A mutant TP53 gene status is associated with a poor prognosis and anthracycline resistance in breast cancer patients. Eur. J. Cancer. 39:2003;447-453
31. Bergh J., Norberg T., Sjogren S., Lindgren A., Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat. Med. 1:1995;1029-1034
32. Kucera E., Speiser P., Gnant M., Szabo L., Samonigg H., Hausmaninger H.V., et al. Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node and steroid receptor positive breast cancer patients. Eur. J. Cancer. 35:1999;398-405
33. Blons H., Laurent-Puig P. TP53 and head and neck neoplasms. Hum. Mutat. 21:2003;252-257. [review]
34. Gasco M., Crook T. The p53 network in head and neck cancer. Oral Oncol. 39:2003;222-231. [review]
35. Alsner J., Sørensen S.B., Overgaard J. TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck. Radiother. Oncol. 59:2001;179-185
36. Skaug V., Ryberg D., Kure E.H., Arab M.O., Stangeland L., Myking A.O., et al. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients. Clin. Cancer Res. 6:2000;1031-1037
37. Campling B.G., El-Deiry W.S. Clinical implication of p53 mutation in lung cancer. Mol. Biotechnol. 24:2003;141-156
38. Huncharek M., Kupelnick B., Geschwind J.F., Caubet J.F. Prognostic significance of p53 mutations in non-small cell lung cancer: a meta-analysis of 829 cases from eight published studies. Cancer Lett. 153:2000;219-226
39. Inoue A., Narumi K., Matsubara N., Sugawara S.-I., Saijo Y., Satoh K., et al. Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drugs in human lung cancer cells irrespective of the status of p53 gene. Cancer Lett. 157:2000;105-112
40. Brattstrom D., Bergqvist M., Lamberg K., Kraaz W., Scheibenflug L., Gustafsson G., et al. Complete sequence of p53 gene in 20 patients with lung cancer: comparison with chemosensitivity and immunohistochemistry. Med. Oncol. 15:1998;255-261
41. Staib F., Hussain S.P., Hofseth L.J., Wang X.W., Harris C.C. TP53 and liver carcinogenesis. Hum. Mutat. 21:2003;201-216. [review]
42. Tommasino M., Accardi R., Caldeira S., Dong W., Malanchi I., Smet A., et al. The role of tp53 in cervical carcinogenesis. Hum. Mutat. 21:2003;307-312. [review]
43. Ishikawa H., Mitsuhashi N., Sakurai H., Maebayashi K.M., Niibe H. The effects of p53 status and human pappilloma virus infection on the clinical outcome of patients with stage IIIB cervical carcinoma treated with radiation therapy alone. Cancer. 91:2001;80-89
44. Giglia-Mari G., Sarasin A. TP53 mutations in human skin cancers. Hum. Mutat. 21:2003;217-228. [review]
45. Temam S., Flahault A., Perie S., Monceaux G., Coulet F., Callard P., et al. p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J. Clin. Oncol. 18:2000;385-394
46. Schuijer M., Berns E.M.J.J. TP53 and ovarian cancer. Hum. Mutat. 21:2003;285-291. [review]
47. Caserini C., Pratesi G., Tortoreto M., Bedogne B., Carenini N., Supino R., et al. Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies. Clin. Cancer Res. 3:1997;955-961
48. Reles A., Wen W.H., Schmider A., Gee C., Runnebaum I.B., Kilian U., et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin. Cancer Res. 7:2001;2984-2997
49. Laframboise S., Chapman W., McLaughlin J., Andrulis I.L. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance. Cancer J. 6:2000;302-308
50. Wilson PK. Development of an optical biosensor for the detection of clinically relevant mutations in the TP53 gene, Medical Diagnostic MDc thesis, supervisor: Prof. A.P.F. Turner, submitted for publication, 1 September 2003, Cranfield University Silsoe, UK.
51. Ahrendt S.A., Halachmi S., Chow J.T., Wu L., Halachmi N., Yang S.C., et al. Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. PNAS. 96:1999;7382
52. Duddy P.M., Hanby A.M., Barnes D.M., Camplejohn R.S. Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay. J. Mol. Diagnostics. 2(3):2000;139-144
53. Narayanaswami G., Taylor P.D. Site-directed mutagenesis of exon 5 of p53: purification, analysis, and validation of amplicons for DHPLC. Genet. Test. 6(3):2002;177-184
54. Gross E., Kiechle M., Arnold N. Mutation analysis of p53 in ovarian tumors by DHPLC. J. Biochem. Biophys. Methods. 47(1-2):2001;73-81
55. Huang J., Kirk B., Favis R., Soussi T., Paty P., Cao W., et al. An endonuclease/ligase based mutation scanning method especially suited for analysis of neoplastic tissue. Oncogene. 21(12):2002;1909-1921
56. Goldrick M.M., Kimball G.R., Liu Q., Martin L.A., Sommer S.S., Tseng J.Y. NIRCA: a rapid robust method for screening for unknown point mutations. BioTechniques. 21(1):1996;106-112
57. Miyajima K., Tamiya S., Oda Y., Adachi T., Konomoto T., Toyoshiba H., et al. Relative quantitation of p53 and MDM2 gene expression in leiomyosarcoma; real-time semi-quantitative reverse transcription-polymerase chain reaction. Cancer Lett. 164(2):2001;177-188
58. Ru Q.H., Jing H.E., Luo G.A., Huang Q. Single-strand conformation polymorphism analysis to detect the p53 mutation in colon tumor samples by capillary electrophoresis. J. Chromatogr., A. 894(1-2):2000;171-177
59. Sheffield V.C., Cox D.R., Lerman L.S., Myers R.M. Attachment of a 40-base-pair G+C-rich sequence (GC-clamp) to genomic DNA fragments by the polymerase chain reaction results in improved detection of single-base changes. Proc. Natl. Acad. Sci. U. S. A. 86:1989;232-236
60. Van Orsouw N.J., Dhanda R.K., Rines R.D., Smith W.M., Sigalas I., Eng C., et al. Rapid design of denaturing gradient-based two-dimensional electrophoretic gene mutational scanning tests. Nucleic Acids Res. 26:1998;2398-2406
61. Ekstrom P.O., Wasserkort R., Minarik M., Foret F., Thilly W.G. Two-point fluorescence detection and automated fraction collection applied to constant denaturant capillary electrophoresis. BioTechniques. 29(3):2000;5824-5869
62. Kaur M., Zhang Y., Liu W.H., Tetradis S., Price B.D., Makrigiorgos G.M. Ligation of a primer at a mutation: a method to detect low level mutations in DNA. Mutagenesis. 17(5):2002;365-374
63. Kaserer K., Schmaus J., Bethge U., Migschitz B., Fasching S., Walch A., et al. Staining patterns of p53 immunohistochemistry and their biological significance in colorectal cancer. J. Pathol. 190(4):2000;450-456
64. Schwartz H., Alvares C.P., White M.B., Fields S. Mutation detection by a two-hybrid assay. Hum. Mol. Genet. 7(6):1998;1029-1032
65. Askari M., Alarie J.P., Moreno-Bondi M., Vo-Dinh T. Application of an antibody biochip for p53 detection and cancer diagnosis. Biotechnol. Prog. 17(3):2001;543-552
66. Persson B., Stenhag K., Nilsson P., Larsson A., Uhlén M., Nygren P. Analysis of oligonucleotide probe affinities using surface plasmon resonance: a means for mutational scanning. Anal. Biochem. 246:1997;34-44
67. Marrazza G., Chiti G., Mascini M., Anichini M. Detection of human apolipoprotein E genotypes by DNA electrochemical biosensor coupled with PCR. Clin. Chem. 46(31):2000;7
68. Marrazza G., Tombelli S., Mascini M., Manzoni A. Detection of human apolipoprotein E genotypes by DNA biosensors coupled with PCR. Clin. Chim. Acta. 307:2001;241-248
69. Minunni M., Tombelli S., Scielzi R., Mannelli I., Mascini M., Gaudiano C. Detection of beta-thalassemia by a DNA piezoelectric biosensor coupled with PCR. Anal. Chim. Acta. 481(1):2003;55-64
70. Palacek E., Fojta M., Tomschik M., Wang J. Electrochemical biosensor for DNA hybridization and DNA damage. Biosens. Bioelectron. 13:1998;621-628
71. Wang J., Rivas G., Cai X., Chicharro M., Parrado C., Dontha N., et al. Detection of point mutation in the p53 gene using a peptide nucleic acid biosensor. Anal. Chim. Acta. 344:1997;111-118
72. Miyahara H., Yamashita K., Kanai M., Uchida K., Takagi M., Kondo H., et al. Electrochemical analysis of single nucleotide polymorphisms of p53 gene. Talanta. 56:2002;829-835
73. Wang J., Nielsen P.E., Jiang M., Cai X., Fernandes J., Grant D., et al. Mismatch sensitive hybridization detection by peptide nucleic acids immobilized on a quartz crystal microbalance. Anal. Chem. 69:1997;5200-5202
74. Wittung-Shafshede P., Rodahl M., Kasemo B., Nielsen P., Norden B. Detection of point mutation in DNA by NA-based quartz crystal biosensor. Colloids Surf., A Physicochem. Eng. Asp. 174:2000;269-273
75. Nilsson P., Persson B., Larsson A., Uhlen M., Nygren P.A. Detection of mutations in PCR products from clinical samples by surface plasmon resonance. J. Mol. Recognit. 10(1):1997;7-17
76. Nilsson P., Larsson A., Lundeberg J., Uhlen M., Nygren P.A. Mutational scanning of PCR products by subtractive oligonucleotide hybridization analysis. BioTechniques. 26(2):1999;308-316
77. McGlennen R.C. Miniaturization technologies for molecular diagnostics. Clin. Chem. 47(3):2001;393-402
78. Wen W.H., Bernstein L., Lescallett J., Beazer-Barclay Y., Sullivan-Halley J., White M., et al. Comparison of TP53 mutations identified by oligonucleotide microarray and conventional DNA sequence. Anal. Cancer Res. 60:2000;2716-2722
79. Takahashi Y., Ishii Y., Nagata T., Ikarashi M., Ishikawa K., Asai S. Clinical application of oligonucleotide probe array for full-length gene sequencing of TP53 in colon cancer. Oncology. 64(1):2003;54-60
80. Wolf P., Hu Y.C., Doffek K., Sidransky D., Ahrendt S.A. O(6)-Methylguanine-DNA methyltransferase promoter hypermethylation shifts the p53 mutational spectrum in non-small cell lung cancer. Cancer Res. 61(22):2001;8113-8117
81. Wikman F.P., Lu M.L., Thykjaer T., Olesen S.H., Andersen L.D., Cordon-Cardo C., et al. Evaluation of the performance of a p53 sequencing microarray chip using 140 previously sequenced bladder tumor samples. Clin. Chem. 46(10):2000;1555-1561
82. Takahashi Y., Ishii Y., Nagata T., Ikarashi M., Ishikawa K., Asai S. Clinical application of oligonucleotide probe array for full-length gene sequencing of TP53 in colon cancer. Oncology. 64(1):2003;54-60